Navigation Links
Dendreon Announces Increased Capacity and Significant Reimbursement Decisions Supporting Broad Availability of PROVENGE
Date:6/30/2011

SEATTLE, June 30, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).  

  • The U.S. Food and Drug Administration (FDA) approved the Los Angeles immunotherapy manufacturing facility on June 29, 2011. The facility includes 36 workstations, and Dendreon will bring these on in a staged approach.
  • In addition, the Centers for Medicare and Medicaid Services (CMS) issued a final National Coverage Decision (NCD) for PROVENGE on June 30, 2011, requiring Medicare contractors to cover the use of PROVENGE for treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. The NCD will standardize coverage processes across the country for all Medicare patients with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer and provides the local Medicare Administrative Contractors (MACs) specific criteria, consistent with the label, on how PROVENGE should be covered.
  • PROVENGE was issued a product specific Q-code effective July 1, 2011, which allows for electronic submission of claims and is expected to accelerate time to payment for physicians.  
  • As part of this expanded access, Dendreon supports programs to provide comprehensive assistance for eligible patients seeking access to treatment with PROVENGE, including through grants to independent foundations and establishment of a patient assistance program for uninsured patients. Dendreon provides grants to independently run foundations providing qualifying patients with fin
    '/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... participants committed to not only creating unique business card ... tweaking and testing virtual models and 3D test prints ... “I enjoyed being involved as a judge,” stated a ... a commendable range exploring the technical capabilities of the ... the creativity of the contestants.” , Array Architects is ...
(Date:10/1/2014)... Irvine, CA (PRWEB) September 30, 2014 ... for user-friendly, cost-effective tools to address sales, training ... PMG has developed innovative mobile applications to ... studies, outlining the agency’s latest customized mobile app ... http://www.studiopmg.com/work . , In partnership with Toyota, ...
(Date:10/1/2014)... 30, 2014 Award winning unified ... announces four new-hosted collaboration bundles that combine next ... quality conferencing experiences for low, flat rate fees. ... from, businesses have optimized solutions to meet their ... include audio only minutes (1K, 5K, 10K increments) ...
(Date:10/1/2014)... October 01, 2014 TeselaGen Biotechnology ... Science Foundation to expand their bioCAD/CAM software suite, which ... modify DNA. The Small Business Innovation Research Phase II ... technology under exclusive license from the Lawrence Berkeley National ... Institute , an LBNL laboratory that develops alternative fuel ...
Breaking Biology Technology:Array Architects Challenges Staff to Create with 3D Printer 2Digital Agency Studio PMG Launches New Case Studies on Website 2SoundConnect Launches New Audio, Web and Video Bundles 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... the pro and cons of radio frequency identification technology ... at the second annual Wisconsin RFID Conference. Sponsored by ... at the steps for implementing RFID and predicted where ... about a product in an electronic tag. The tags ...
... MILWAUKEE - Metavante Corporation , a supplier of ... Corporation , has acquired two financial firms located in Virginia ... purchased GHR Systems , a provider of loan origination ... million and the deal is expected to close in the ...
... Wis. - It would be misleading to suggest that ... human embryos. They arent. In fact, no scientist in the ... ,It would also be disingenuous to suggest the process for ... at the outset -- from the process used in ...
Cached Biology Technology:Conference studies applications and lessons of RFID 2Conference studies applications and lessons of RFID 3The Attack of the Clones: No, its not a summer movie 2The Attack of the Clones: No, its not a summer movie 3
(Date:10/1/2014)... Reserve University researchers hope to take a healthy salad ... aggressive form of breast cancer in leafy greens. , ... the vaccine either by eating the salad or making ... assistant professor of biomedical engineering at Case Western Reserve ... The Susan G. Komen breast cancer organization is funding ...
(Date:10/1/2014)... 2014 Novel detection technology ... field  The life science field has ... the years. Some are shooting stars and others ... novel detection technology that has raised much enthusiasm ... technology is becoming commercially available. With their unique ...
(Date:9/30/2014)... visit the Mediterranean each year, but its deep-blue ... Earth. Almost 1,000 alien species, including fish, crustaceans, ... through human activities. In the open-access journal ... of researchers analyzed data from a new information ... how the introduction of alien species has changed ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3First-of-a-kind Solution for Utilizing Photon Upconversion 2Biodiversity in the Mediterranean is threatened by alien species 2
... bacteria that break down pollutants do their job and ... toxic wastes. , Bacteria called Dehalococcoides ethenogenes, discovered in ... professor of civil and environmental engineering, and isolated and ... now in wide use to detoxify such carcinogenic chemicals ...
... announced the publication in the June 23 issue of the ... gene therapy trial for Parkinson’s disease and the first report ... for any adult neurodegenerative disease. , The open label ... disease demonstrated both a lack of adverse events related to ...
... in the United States and other northern mid- ... in offsetting global warming than previously thought, according ... The study, which sheds light on the so-called ... are removing an unexpectedly high proportion of carbon ...
Cached Biology News:Helping chlorine-eating bacteria clean up toxic waste 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 2Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 3Gene therapy study shows safety and statistically significant improvement in Parkinson's disease 4Scientists close in on missing carbon sink 2Scientists close in on missing carbon sink 3
Applications: Epitope mapping, Mapping protein-protein contacts, Identification of enzyme substrates/inhibitors, Identification of receptor agonists/antagonists...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: